BRPI0117180B8 - composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior - Google Patents

composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior

Info

Publication number
BRPI0117180B8
BRPI0117180B8 BR0117180A BR0117180A BRPI0117180B8 BR PI0117180 B8 BRPI0117180 B8 BR PI0117180B8 BR 0117180 A BR0117180 A BR 0117180A BR 0117180 A BR0117180 A BR 0117180A BR PI0117180 B8 BRPI0117180 B8 BR PI0117180B8
Authority
BR
Brazil
Prior art keywords
coating layer
poly
methyl methacrylate
methacrylic acid
human
Prior art date
Application number
BR0117180A
Other languages
English (en)
Other versions
BR0117180A (pt
BRPI0117180B1 (pt
Inventor
Gary Newby Daniel
Paul Dittmar Gregory
Michael Amante Joseph
Ryan Cronk Tony
Original Assignee
Procter & Gamble
Warner Chilcott Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32823137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0117180(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble, Warner Chilcott Co Llc filed Critical Procter & Gamble
Publication of BR0117180A publication Critical patent/BR0117180A/pt
Publication of BRPI0117180B1 publication Critical patent/BRPI0117180B1/pt
Publication of BRPI0117180B8 publication Critical patent/BRPI0117180B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"forma de dosagem farmacêutica com múltiplos revestimentos". a presente invenção refere-se a uma composição farmacêutica com forma de dosagem em unidade sólida para administração oral a um ser humano ou animal inferior, que consiste em: a. uma quantidade segura e eficaz de um agente terapeuticamente ativo; b. uma camada de revestimento interna selecionada a partir do grupo consistindo em poli(ácido metacrílico, metacrilato de metila) 1:2, poli(ácido metacrílico, metacrilato de metila) 1:1, e misturas dessas substâncias; e c. uma camada de revestimento externa consistindo em um matedal como um polímero entérico ou uma película de revestimento; sendo que a camada de revestimento interna não é igual à camada de revestimento externa; sendo que, se a camada de revestimento interna é poli(ácido metacrílico, metacrilato de metila) 1:1, então a camada de revestimento externa não é poli(ácido metacrílico, metacrilato de metila) 1:2 nem uma mistura de poli(ácido metacrílico, metacrilato de metila) 1:1 e poli(ácido metacrílico, metacrilato de metila) 1:2; e sendo que a camada de revestimento interna e a camada de revestimento externa não contêm qualquer agente terapeuticamente ativo. esta invenção refere-se, também, a um método para manutenção do local de aplicação desejado de um agente terapêutico no trato gastrointestinal, pela administração das composições acima descritas a um ser humano ou animal inferior.
BR0117180A 2001-11-23 2001-11-23 composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior BRPI0117180B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/043893 WO2003045356A1 (en) 2000-11-20 2001-11-23 Pharmaceutical dosage form with multiple coatings

Publications (3)

Publication Number Publication Date
BR0117180A BR0117180A (pt) 2004-11-03
BRPI0117180B1 BRPI0117180B1 (pt) 2018-12-04
BRPI0117180B8 true BRPI0117180B8 (pt) 2021-05-25

Family

ID=32823137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0117180A BRPI0117180B8 (pt) 2001-11-23 2001-11-23 composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior

Country Status (15)

Country Link
EP (1) EP1453487B2 (pt)
JP (1) JP4999037B2 (pt)
CN (1) CN1314390C (pt)
AT (1) ATE389389T1 (pt)
AU (1) AU2002226955B2 (pt)
BR (1) BRPI0117180B8 (pt)
DE (1) DE60133319T3 (pt)
DK (1) DK1453487T3 (pt)
ES (1) ES2301575T5 (pt)
HU (1) HU231030B1 (pt)
IL (1) IL161628A (pt)
MX (1) MXPA04004747A (pt)
NZ (1) NZ532564A (pt)
PT (1) PT1453487E (pt)
WO (1) WO2003045356A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
GB2407501A (en) * 2003-11-03 2005-05-04 Ist Superiore Sanita Nanoparticles for delivery of a pharmacologically active agent, comprising water insoluble (co)polymer core & hydrophilic acrylate-based (co)polymer shell
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
KR20080085924A (ko) * 2004-09-01 2008-09-24 더 프록터 앤드 갬블 캄파니 5-아미노-2-하이드록시벤조산 및 환원당을 함유하는 조성물
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
JP5799299B2 (ja) 2007-02-01 2015-10-21 ザ・アイムス・カンパニーＴｈｅ Ｉａｍｓ Ｃｏｍｐａｎｙ ブドウ糖代謝拮抗物質、アボカド又はアボカド抽出物を使用する、哺乳動物における炎症及びストレスの低下方法
WO2008135090A1 (en) 2007-05-07 2008-11-13 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2012107058A (ja) * 2012-02-27 2012-06-07 Warner Chilcott Co Llc 複数のコーティングを有する医薬剤形
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
GB2510754B (en) * 2013-02-12 2016-07-13 Diurnal Ltd Controlled drug release
US20150374632A1 (en) 2013-02-22 2015-12-31 Zeria Pharmaceutical Co., Ltd. Enteric coated tablet
JP6165022B2 (ja) * 2013-10-30 2017-07-19 株式会社ファンケル 放出制御型ソフトカプセル剤
WO2016001843A1 (en) * 2014-06-30 2016-01-07 Sun Pharmaceutical Industries Limited Extended-release gastroretentive tablets of voglibose
EP3162362A1 (de) * 2015-10-30 2017-05-03 Dr. Falk Pharma Gmbh Optimierte mesalazinhaltige hochdosistablette
CN107661370A (zh) * 2017-11-20 2018-02-06 贵州浩诚药业有限公司 一种苦参片及其制备方法
EP3787606A1 (en) * 2018-05-03 2021-03-10 M W Encap Limited Dosage forms for delivery of medicines to the lower gastrointestinal tract
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
US11523992B2 (en) * 2019-05-15 2022-12-13 Evonik Operations Gmbh Process for preparing filled hard-shell capsules with (meth)acrylate copolymer based coatings with a capsule-filling machine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
IT1246382B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
AU5310898A (en) * 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets

Also Published As

Publication number Publication date
BR0117180A (pt) 2004-11-03
EP1453487B1 (en) 2008-03-19
BRPI0117180B1 (pt) 2018-12-04
DK1453487T3 (da) 2008-07-21
EP1453487B2 (en) 2021-03-31
MXPA04004747A (es) 2004-08-02
JP4999037B2 (ja) 2012-08-15
PT1453487E (pt) 2008-05-13
HUP0402230A3 (en) 2008-04-28
JP2005510539A (ja) 2005-04-21
AU2002226955A1 (en) 2003-06-10
IL161628A (en) 2014-03-31
HUP0402230A2 (hu) 2005-02-28
ATE389389T1 (de) 2008-04-15
ES2301575T3 (es) 2008-07-01
EP1453487A1 (en) 2004-09-08
WO2003045356A1 (en) 2003-06-05
DE60133319D1 (de) 2008-04-30
DE60133319T2 (de) 2009-04-30
NZ532564A (en) 2006-06-30
CN1558754A (zh) 2004-12-29
CN1314390C (zh) 2007-05-09
ES2301575T5 (es) 2022-04-22
IL161628A0 (en) 2004-09-27
AU2002226955B2 (en) 2006-04-27
HU231030B1 (hu) 2019-12-30
DE60133319T3 (de) 2021-08-05

Similar Documents

Publication Publication Date Title
BRPI0117180B8 (pt) composição farmacêutica em uma forma de unidade sólida de dosagem para a administração oral a um ser humano ou animal inferior
CA2359812A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20180344743A1 (en) Methods of treatment of anorectal and genital disorders
JP2018529762A (ja) 異常炎症反応に関連する状態を処置するための方法および組成物
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
BR0008137A (pt) Composição de droga bioadesiva de liberação prolongada e processos para administrar um agente terapêutico e para preparar uma composição de droga bioadesiva de liberação prolongada
BRPI0408999A (pt) comprimidos prensados de multiparticulados de liberação oral prolongada
WO2021188564A1 (en) Methods of treating covid-19 with a niclosamide compound
JPWO2002024161A1 (ja) 直腸下部滞留型坐剤
HUP9903732A2 (hu) cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására
JPS6261917A (ja) アリ−ルプロピオン酸誘導体の経皮的に吸収しうる含水製剤とその製造方法
BR0315573A (pt) Método para tratar, prevenir, controlar e/ou modificar dor em um paciente e composição farmacêutica
JP2006516571A5 (pt)
BRPI0609929A2 (pt) método transdérmico e esparadrapo para náusea
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
BR9809694A (pt) Processo e composição para administração de taxanos oralmente a pacientes humanos
AR046410A1 (es) Composiciones farmaceuticas para la liberacion modificada de modafinilo
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
BRPI0415725A (pt) formulação aspergìvel transdérmica, método para administrar um agente farmaceuticamente ativo e método para formar uma pelìcula farmaceuticamente ativa
JP2004131495A (ja) 非ステロイド系抗炎症剤の局所送達用医薬組成物
JP3575033B2 (ja) 外用剤
ATE462419T1 (de) Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
CA2444814A1 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
JPS59184122A (ja) アクリル系膏体

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25E Requested change of name of applicant rejected

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/11/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23/11/2021

B25E Requested change of name of applicant rejected

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870220023198 DE 17/03/2022, EM VIRTUDE DA EXTINCAO (21.1) ART. 78 INCISO I DA LPI PUBLICADA NA RPI 2696 DE 06/09/2022.

B25B Requested transfer of rights rejected

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870220023211 DE 17/03/2022, EM VIRTUDE DA EXTINCAO (21.1) ART. 78 INCISO I DA LPI, PUBLICADA NA RPI2696 DE 06/09/2022.